Piperacillin-Tazobactam Pediatric Dose — Antimicrobials
Piperacillin-tazobactam is a broad-spectrum beta-lactam/beta-lactamase inhibitor combination antibiotic that extends piperacillin’s activity against beta-lactamase-producing organisms, including many gram-negative bacilli, anaerobes, and select gram-positive pathogens. It is commonly used in pediatric patients for serious or complicated infections such as intra-abdominal infections, healthcare-associated pneumonia, febrile neutropenia, and polymicrobial sepsis.
Pediatric Dosing
- Dose: 80 mg/kg/dose IV every 8 hours (dosed as the piperacillin component)
- Adult dose: 3 g/dose IV every 8 hours
For a 20 kg child: 20 × 80 mg/kg = 1,600 mg per dose IV every 8 hours. The adult dose ceiling of 3 g/dose should be referenced for larger pediatric patients or adolescents approaching adult weight; consult institutional protocol for weight-based cap and maximum dose guidance.
Indications and Clinical Context
Piperacillin-tazobactam is indicated for moderate-to-severe pediatric infections requiring broad-spectrum gram-negative, anaerobic, and beta-lactamase-resistant coverage. Common indications include complicated intra-abdominal infections, hospital-acquired or ventilator-associated pneumonia, complicated urinary tract infections, skin and soft tissue infections, and empiric therapy in febrile neutropenia. Its broad activity makes it a preferred agent in PICU and oncology settings when polymicrobial or resistant organisms are a concern.
Selection of this agent should be guided by local antibiogram data, clinical severity, and site of infection. De-escalation to a narrower-spectrum agent is encouraged once culture and sensitivity results are available, in accordance with antimicrobial stewardship principles.
Administration and Monitoring
Piperacillin-tazobactam is administered exclusively by the intravenous (IV) route, typically as an intermittent infusion over 30 minutes; extended infusion protocols (e.g., over 3–4 hours) may be used at some institutions to optimize pharmacodynamic target attainment for resistant organisms — consult institutional protocol. Dose frequency should be adjusted in patients with renal impairment.
- Monitoring: Renal function (SCr, BUN), hepatic enzymes, CBC for prolonged courses (risk of neutropenia)
- Common adverse effects: Diarrhea, rash, elevated liver enzymes, hypokalemia, thrombocytopenia with prolonged use
- Key contraindication: Hypersensitivity to penicillins or beta-lactams; use with caution in patients with cephalosporin allergy
- Max dose: Adult dose is 3 g/dose IV every 8 hours; consult institutional protocol for weight-based maximum in pediatric patients
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.